Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Yunkang Group Limited ( (HK:2325) ) has shared an announcement.
Yunkang Group Limited reported a decline in revenue for the year ended December 31, 2025, with total revenue falling 15.5% year on year to RMB601.4 million, mainly due to a 28.1% drop in diagnostic outsourcing services and softer demand across its other diagnostic segments. Despite lower gross profit, the company swung from a substantial loss in 2024 to a modest profit in 2025, posting net profit of RMB3.9 million and basic and diluted earnings per share of RMB0.005, signaling a notable recovery in profitability that may ease concerns among shareholders about the sustainability of its operations.
The most recent analyst rating on (HK:2325) stock is a Hold with a HK$0.83 price target. To see the full list of analyst forecasts on Yunkang Group Limited stock, see the HK:2325 Stock Forecast page.
More about Yunkang Group Limited
Yunkang Group Limited is a healthcare diagnostic services provider based in China, offering diagnostic testing for medical institution alliances, diagnostic outsourcing services, and testing for non-medical institutions. The group operates through a network model that supports hospitals and other organizations with laboratory and testing capabilities, positioning it within the broader medical and clinical diagnostics industry.
Average Trading Volume: 1,260,008
Technical Sentiment Signal: Sell
Current Market Cap: HK$509.4M
For an in-depth examination of 2325 stock, go to TipRanks’ Overview page.